Management of Parkinson's disease in the acute hospital environment

Journal of the Royal College of Physicians of Edinburgh

Volumn 42, Issue 2, 2012, Pages 157-162

  MacMahon, M J ^a   MacMahon, D G ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Acute illness; Deep brain stimulation; Dopamine agonist withdrawal; Parenteral dopamine agonist; Parkinson's disease; Uroleptic malignant like syndrome

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE DERIVATIVE; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; QUETIAPINE; RASAGILINE; ROTIGOTINE; SELEGILINE;

ASPIRATION PNEUMONIA; BRAIN DEPTH STIMULATION; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DYSKINESIA; ESSENTIAL TREMOR; EXTRAPYRAMIDAL SYNDROME; FLUID THERAPY; HEALTH CARE NEED; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; HYPERPYREXIA; HYPERTHERMIA; MEDICAL RECORD REVIEW; MYOCLONUS; NEEDS ASSESSMENT; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPHARMACOLOGY; OXYGEN THERAPY; PARKINSON DISEASE; PARKINSONISM; PATIENT ASSESSMENT; PRESCRIPTION; PSYCHOSIS; REVIEW; RIGIDITY; SCREENING TEST; SHOCK; SIDE EFFECT; THERAPY EFFECT; VOMITING;

EID: 84864249974     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/jrcpe.2012.215     Document Type: Review

References (26)

1. Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 2005; 20:1104-8. http:// dx.doi.org/10.1002/mds.20485
2. Gerlach OH, Winogrodzka A, Weber WE. Clinical problems in the hospitalized Parkinson's disease patient: systematic review. Mov Disord 2011; 26:197-208. http://dx.doi.org/10.1002/mds.23449
3. National Institute for Health and Clinical Excellence. Parkinson's disease. Diagnosis and management in primary and secondary care [Internet]. London: NICE; 2006 [cited 2012 May 3]. Available from: www.nice.org.uk/CG035
4. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28:99-102. http://dx.doi.org/10.1093/ageing/28.2.99
5. Hughes AJ, Daniel SE, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-4. http://dx. doi.org/10.1136/jnnp.55.3.181
6. Quinn N. Parkinsonism: recognition and differential diagnosis. BMJ 1995; 310:447-52. http://dx.doi.org/10.1136/bmj.310.6977.447
7. Tyrrell P, Rossor M. The association of gegenhalten in the upper limbs with dyspraxia. J Neurol Neurosurg Psychiatry 1988; 51:995-7. http://dx.doi.org/10.1136/jnnp.51.7.995
8. Grosset DG, Macphee GJ, Nairn M. Diagnosis and pharmacological management of Parkinson's disease: summary of SIGN guidelines. BMJ 2010; 340:b5614. http://dx.doi.org/10.1136/bmj.b5614
9. Aminoff MJ, Christine CW, Friedman JH et al. Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord 2011; 17:139-45. http://dx.doi.org/10.1016/j.parkreldis.2010.11.009
10. Parkinson's UK. 'Get it on time' campaign [Internet]. London: Parkinson's UK [cited 2012 Apr 5]. Available from: http://www. parkinsons.org.uk/default.aspx?page=7655
11. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56:S1-S88.
12. Brennan KA, Genever RW. Managing Parkinson's disease during surgery. BMJ 2010; 341:c5718. http://dx.doi.org/10.1136/bmj.c5718
13. LeWitt PA, Boroojerdi B, MacMahon D. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson's disease. Clinical Neuropharmacol 2007; 30:256-65. http://dx.doi.org/10.1097/wnf.0b013e318154c7c4
14. BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain. British National Formulary. 60th ed. London: BMJ Publishing Group; 2010.
15. Nicholson G, Pereira AC, Hall GM. Parkinson's disease and anaesthesia. Br J Anaesth 2002; 89:904-16. http://dx.doi.org/10.1093/ bja/aef268
16. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85:129-35. http://dx.doi.org/10.1093/ bja/85.1.129
17. Stotz M, Thümmler D, Schürch M et al. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of anti-Parkinsonian medication. Br J Anaesth 2004; 93:868-71. http:// dx.doi.org/10.1093/bja/aeh269
18. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001; 16:960-2. http:// dx.doi.org/10.1002/mds.1166
19. Ghosh R, Liddle BJ. Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome. Postgrad Med J 2011; 87:125-31. http://dx.doi.org/10.1136/ pgmj.2010.104976
20. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361:62-72. http://dx.doi.org/10.1056/ NEJMra0801327
21. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67:58-63. http:// dx.doi.org/10.1001/archneurol.2009.294
22. Lindahl AJ, MacMahon DG. Managing dopamine agonist withdrawal syndrome in Parkinson's disease. Prog Neurol Psychiatry 2011; 15:4.
23. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007; 83:384-8. http://dx.doi.org/10.1136/ pgmj.2006.054759
24. Miller N, Noble E, Jones D et al. Hard to swallow: dysphagia in Parkinson's disease. Age Ageing 2006; 35:614-8. http://dx.doi. org/10.1093/ageing/afl105
25. Kwong JC, Howden BP, Charles PG. New aspirations: the debate on aspiration pneumonia treatment guidelines. Med J Aust 2011; 195:380-1. http://dx.doi.org/10.5694/mja11.10298
26. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol. Forthcoming 2012.